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Retrospective Evaluation of Dosing Body Weight for Unfractionated Heparin in Obese Patients
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ABSTRACT
Purpose: Using adjusted body weight (AdjBW) for heparin dosing in obese patients is a
common but not validated clinical practice. The purpose of this study was to evaluate whether
using AdjBW in obese patients would lead to quick achievement of therapeutic activated partial
thromboplastin time (aPTT) and low bleeding risk with heparin therapy.
Methods: A retrospective cohort study was conducted in patients that received heparin before
and after implementation of a revised heparin protocol that utilized AdjBW for obese patients.
The primary outcome was percentage of first aPTT values within the therapeutic range.
Secondary outcomes included time to first therapeutic aPTT and clinically significant bleeding.
Results: There was no difference in the primary outcome in obese compared to non-obese
patients in the pre-implementation group (11% vs. 15%) or post implementation group (17% vs.
21%). No difference was seen in time to first therapeutic aPTT between obese and non-obese
patients in either group. However, obese patients in the post-implementation group achieved
therapeutic aPTT significantly faster than obese patients in pre-implementation group (14 vs. 24
hours, p = 0.002). Clinically significant bleeding was higher in obese than non-obese patients
prior to implementation (11% vs. 1%, p = 0.01), but no difference was seen after
implementation.
Conclusion: Although there was no difference in the first aPTT values, more bleeding was seen
in obese patients when actual body weight was used for heparin dose calculation. When AdjBW
was used for dosing in obese patients, it was associated with faster achievement of therapeutic
aPTT.
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Introduction
Despite the availability of newer anticoagulants, unfractionated heparin (heparin) remains
a mainstay anticoagulant for atrial fibrillation, acute coronary syndrome with or without
percutaneous intervention, treatment and prevention of deep vein thrombosis (DVT), pulmonary
embolism (PE), and other thromboembolic disorders.1 For the past two decades, weight-based
heparin dosing nomogram has become the standard practice for treatment of thrombosis, as it has
been shown to achieve rapid anticoagulation and reduce risk of recurrent thrombosis.2 Although
the guidelines endorse the weight-based strategy, they do not specify what dosing weight should
be used or whether a maximum bolus dose or initial infusion rate is recommended for the
treatment of DVT, PE, or atrial fibrillation.3,4,5
The lack of guidance on dosing weight presents a challenge for the obese population,
which comprises one-third of United States adults and correlates to approximately 78.6 million
individuals.6 The weight-based heparin dosing nomogram has not been well studied in these
patients. In addition, literature suggests that using actual body weight (ABW) for heparin dose
calculation in these patients may lead to supratherapeutic activated partial thromboplastin time
(aPTT).7–11 This observation is most likely attributed to the difference in heparin
pharmacokinetics in obese patients. Although the volume of distribution of heparin is similar to
that of blood volume, heparin does not distribute into the less vascular adipose tissue, thus
making it difficult to estimate the volume of distribution for heparin in obese patients.12,13
Therefore, dosing requirements for heparin in obese patients are not directly proportional to their
ABW.
Several strategies have been suggested to account for the difference in heparin dosing
requirements in obese patients. Some studies recommended reducing the initial infusion rate
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with or without reducing the initial bolus dose,14–16 setting a maximum limit for the initial bolus
dose and/or infusion rate,8,10,11 or a combination of both strategies.17,18 In addition, a few case
reports suggested using an adjusted body weight (AdjBW) for heparin dose calculation in obese
patients, although the definition of obesity and formulas to calculate AdjBW varied.19–22
Furthermore, none of the suggested AdjBW had been validated as the most appropriate heparin
dosing weight in obese individuals to achieve quick anticoagulation without increasing risk of
bleeding.
A retrospective evaluation of 79 patients at a 900-bed community teaching hospital
concluded that when a high-intensity heparin protocol (80 units/kg initial bolus followed by 18
units/kg/hour initial infusion rate) was calculated using ABW without a maximum dose limit,
patients who weighed more than 30% above their ideal body weight (IBW) had more first postdose aPTT values above the therapeutic range than those with ABW within 30% above their
IBW.23 When evaluating the mean heparin infusion rate required to achieve a therapeutic aPTT,
the mean infusion rate (units/kg/hour) in obese patients based on AdjBW was similar to the mean
infusion rate in non-obese patients using their ABW. This finding suggested that a dosing
weight using the formula AdjBW = IBW + 0.4 * (ABW-IBW) might be more appropriate for
obese patients. As a result, the high-intensity heparin protocol at this institution was revised to
utilize AdjBW for dose calculation in patients weighing greater than 100 kg. This definition of
obesity was used in the modified protocol instead of ABW more than 30% above IBW, because
ABW is more readily available in the medical charts without the need for manual calculation.
An informal survey to hospitals nationwide showed that many have also made
adjustments to their institutional heparin protocols for obese patients, but the practice varied
from various maximum dose limits to using AdjBW calculated using various formulas (Manny
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Saltiel, Pharm.D, FASHP, FCCP, Regional Clinical Director, Comprehensive Pharmacy
Services, Los Angeles, CA 90036, 2014 March 24). Although a few studies evaluated the
impact of reducing heparin infusion rate and/or setting maximum dose limits in obese
patients,11,14,15,18 to the best of our knowledge no studies have been published to evaluate whether
the use of AdjBW as heparin dosing weight provides better laboratory or clinical outcomes in
this population. The purposes of this study was to 1) confirm the previous finding that patients
who weigh more than 30% above IBW are more likely to be supratherapeutic at their first aPTT
when using ABW for dosing; 2) evaluate whether AdjBW for heparin dosing in obese patients
would lead to quick achievements of anticoagulation and few bleeding events.
METHODS
This retrospective cohort study was conducted at the same 900-bed community teaching
hospital, where the high-intensity heparin protocol was revised to use AdjBW for obese
patients. Prior to data collection, the study was approved by the institutional review boards at the
community teaching hospital where the study was conducted and the university with which the
investigators were affiliated.
Patients
All patients who received the high-intensity heparin protocol from January 2010 to June
2011 and January 2013 to July 2014 were evaluated for eligibility. There was no data collection
between July 2011 and December 2012 to allow time for implementation of the revised highintensity heparin protocol. Patients in the pre-implementation group (January 2010 to June
2011) received high-intensity heparin dose based on ABW regardless of their weight. Those in
the post-implementation group (January 2013 to July 2014) received the revised protocol, where
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AdjBW calculated from IBW + 0.4 * (ABW-IBW) was used for dose calculation in patients
weighing greater than 100 kg.
Inclusion criteria included age 18 years or older, received high-intensity heparin protocol
with a therapeutic aPTT range of 68-95 seconds, and had at least one aPTT measured 6 hours
after the heparin infusion was started. In addition to these inclusion criteria, during the time
period following the implementation of the revised heparin protocol, patients must also receive
heparin dose based on the AdjBW if they weighed more than 30% above their IBW. Due to the
discrepancy in definitions of obesity in the revised heparin protocol and this study, patients were
excluded from the analysis if ABW was used for dosing even though they met the study
definition of obesity (usually due to ABW less than 100 kg). Patients were also excluded if
AdjBW was used for dosing when patients weighed greater than 100 kg even though they did not
meet the study definition of obesity (i.e. ABW within 30% above IBW). Additional exclusion
criteria included pregnancy during heparin treatment, continuation of heparin therapy from
another institution, transition from low-intensity heparin therapy (mainly for cardiac indications,
with lower dosing, a maximum dose limit, and a different aPTT goal) or subcutaneous low-dose
heparin within preceding 48 hours, having received other anticoagulants that could potentially
affect aPTT within 48 hours prior to the initiation of heparin (e.g. argatroban, bivalirudin,
dabigatran), and any violation of the high-intensity heparin protocol (e.g. receiving a customized
heparin regimen, using a weight different from what the protocol specifies) although omission of
the initial bolus dose was allowed.
Eligible patients in both pre-implementation and post-implementation groups were
further categorized into obese and non-obese, which gave the study a total of four cohorts. The
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definition of obesity, for the purpose of this study, was ABW more than 30% above IBW. This
definition was chosen to be consistent with the previous retrospective evaluation.23
Data Collection and Outcomes
The following data were collected for each eligible patient: basic demographic
information (age, sex, height, and weight), indication for heparin use, heparin dosing information
(actual dosing weight, initial bolus dose, infusion rate when therapeutic aPTT was achieved),
baseline and subsequent aPTT values (drawn approximately 6 hours following heparin initiation
and dose changes), baseline hemoglobin and the lowest hemoglobin values during and within 48
hours of discontinuation of heparin therapy, and any overt bleeding events.
The primary outcome was percentage of first aPTT values after initiation of heparin
therapy that were within the therapeutic range. The secondary outcomes included the
percentages of first aPTT values below and above the therapeutic range, percentage of second
aPTT below, within and above the therapeutic range, percentage of patients achieving a
therapeutic aPTT at any time during treatment, median time to first therapeutic aPTT, and
infusion rate required to achieve first therapeutic aPTT. Primary safety outcome was clinically
significant bleeding, which included both major bleeding and clinically relevant nonmajor
bleeding. Major bleeding was defined as overt bleeding associated with a decrease in
hemoglobin of 2 g/dL or more or required a transfusion of 2 or more units of blood, occurred in a
critical site, or contributed to death.24 Clinically relevant nonmajor bleeding was defined as
overt bleeding that did not meet the criteria for major bleeding but warranted treatment or
heparin discontinuation.25
Statistical Analysis
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Based on the previous evaluation, it was determined that 66 patients would be needed in
each of the four cohorts to provide a power of 80% to detect a 20% difference in the primary
outcome between the obese and non-obese cohorts, with a 2-sided alpha level of 0.05.23 The
demographic information was summarized using descriptive statistics and analyzed using t-test
for continuous data and χ2 test for nominal data. The primary outcome and other nominal data
were analyzed using χ2 test. T-test was also used to compare continuous data, such as bolus
doses and aPTT values. The Kruskal-Wallis test was used to compare the median time to first
therapeutic aPTT, while Fisher’s exact test was used to compare clinically significant bleeding
between cohorts. A p value less than 0.05 was considered to be statistically significant. The
statistical analysis was performed with the MedCalc Statistical Software version 15.4 (MedCalc
Software bvba, Ostend, Belgium; https://www.medcalc.org; 2015).
RESULTS
Patient Demographics
Overall, a total of 820 patients were identified as having at least one order for highintensity heparin protocol during the defined time frames (315 patients during the preimplementation period and 505 patients during the after-implementation period). After
eligibility screening, 427 patients were excluded for various reasons (147 in pre-implementation
period and 280 in post-implementation period). The most common reasons were violation of
heparin protocol, received heparin therapy within 48 hours prior to initiation of the high-intensity
heparin protocol, and using dosing weights different from the study definition (primarily in the
post-implementation period). A more detailed breakdown of the excluded patients in both
groups may be found in Figure 1. A total of 393 (168 in pre-implementation group and 225 in
the post-implementation group) were included in the final analysis.
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Other than weight and BMI, baseline characteristics were similar between the obese and
non-obese cohorts in the pre-implementation group, whereas the obese patients in the postimplementation group were younger than the non-obese patients (Table 1). The most common
indication for the high-intensity heparin therapy was venous thromboembolism (VTE), which
included 29% PE, 24% DVT, and 7% both PE and DVT (Table 1). Heparin indications were
similar among the 4 cohorts, except more non-obese patients in the pre-implementation group
received heparin for other miscellaneous thrombosis such as apical thrombus, peripheral arterial
disease, and carotid stenosis.
Pre-Implementation (ABW used for all patients)
Of all 168 patients who received high-intensity heparin protocol in the preimplementation period, only 22 patients (13.1%) achieved therapeutic range with the first aPTT
measurement (Table 2). Fewer obese patients had the first aPTT in the therapeutic range
(10.5%) than non-obese patients (15.2%), but this difference was not statistically different (p =
0.50). This was not affected by whether patients received an initial bolus dose. No statistical
difference was seen in the percentages of first aPTT values above or below the therapeutic
ranges. Second post-dose aPTT values were available in 159 patients (94.6%); 35 of these
(22%) achieved the therapeutic range. Only 7 of all 168 patients (4%) had two consecutive
therapeutic aPTT values (both first and second aPTT values were within the therapeutic range).
Although the second aPTT levels were significantly higher in value in the obese cohort, there
was no statistically significant difference in the percentage of second aPTT below, within or
above the therapeutic range compared to the non-obese cohort. During the course of treatment,
129 patients (76.8%) achieved at least one therapeutic aPTT, but no difference was seen between
the two cohorts. It took less time for the non-obese cohort to obtain first therapeutic aPTT (19.9
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hours), but again this difference was no statistically significant (23.8 hours in obese cohort; p =
0.11). To achieve the first therapeutic aPTT, those in the obese cohort required significantly
lower infusion rate at 14 units/kg/hour whereas the non-obese cohort required 16 units/kg/hour
(p=0.01) (Table 3). If AdjBW were used to calculate the heparin dose required to achieve the
first therapeutic aPTT, the obese patients would require a mean infusion rate of 18.1
units/kg/hour, which is similar to the initial infusion rate for the high-intensity heparin protocol.
Clinically significant bleeding occurred in 8 of 76 obese patients (11%) and in 1 of 92 patients
(1%) in the non-obese cohort (relative risk of 9.7; 95% confidence interval, 1.2-75.7). This
significant finding was driven primarily by major bleeding, 6 (8%) in obese cohort and 1 (1%) in
the non-obese cohort (Table 4).
Post-Implementation (ABW for non-obese patients and AdjBW for obese patients)
Among the 225 patients who received high-intensity heparin after the protocol
modification, 44 (19.6%) patients achieved the therapeutic range at the first aPTT measurement.
Although no statistical difference was seen in the percentages of first aPTT values in the
therapeutic range, significantly fewer obese patients had values above the therapeutic range
(44.2% in obese vs. 59.5% in non-obese, p = 0.04) while more had subtherapeutic values (39%
in obese vs. 19.6% in non-obese, p = 0.003) (Table 2). Second post-dose aPTT values were
available in 204 patients (90.1%). Among these patients, 68 (33%) achieved the therapeutic
range and 19 (8%) had two consecutive therapeutic aPTT values, although no difference was
seen between the obese and non-obese cohorts. Overall, 168 patients (74.7%) achieved at least
one therapeutic aPTT at any given time during the course of treatment, but no difference was
seen between the two cohorts. Patients in the obese cohort achieved the first therapeutic aPTT
more quickly (14 hours) than those in the non-obese cohort (17.3 hours), but this difference was

11

not statistically significant (p = 0.47). The infusion rate required to achieve the first aPTT in the
obese cohort was 18.2 units/kg/hour compared to 16.5 units/kg/hour in the non-obese cohort
(p=0.008). No difference was seen in clinically significant bleeding between the two cohorts.
The breakdown of major and nonmajor bleeding is provided in Table 4.
Pre-Implementation versus Post-Implementation
The data from pre-implementation period were compared with those from the postimplementation period to evaluate whether the protocol modification improved heparin dosing in
obese patients. When comparing the first aPTT values, obese patients had similar percentages of
therapeutic values before and after the protocol modification. However, fewer patients had
supratherapeutic values after the protocol modification, whereas more had subtherapeutic values
(Figure 2). In addition, more obese patients in the post-implementation than the preimplementation period achieved the therapeutic range at the second aPTT measurement (37.5%
vs. 17.8%, p = 0.02). This was also reflected in more rapid achievement of therapeutic aPTT (<
24 hours) after protocol modification in the obese population (Table 5). However, the protocol
modification did not result in a reduction of clinically significant bleeding in obese patients.
DISCUSSION
To the best of our knowledge, this is the first study to evaluate whether using AdjBW in
heparin dose calculation improves anticoagulation while minimizing bleeding risk in obese
patients. Our study did not show a significant difference in aPTT values below, within, or above
the therapeutic range between obese and non-obese patients when ABW was used for heparin
dose calculation. Although we did not confirm the earlier findings that using ABW for heparin
dosing in obese patients resulted in higher percentage of supratherapeutic aPTT, this is the first
study to demonstrate that this dosing strategy was associated with a significant increase in
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clinically significant bleeding. Our data from the pre-implementation group also suggested that
using AdjBW to calculate the initial infusion rate in obese patients would result in a dose close to
the infusion rate required to achieve the first therapeutic aPTT.
When the post-implantation group was analyzed, with AjBW used for heparin dosing in
obese patients, it did not actually improve the percentage of patients achieving therapeutic range
with the first or second aPTT measurements as expected. Interestingly, fewer obese patients had
supratherapeutic aPTT while more had subtherapeutic aPTT at the first measurement, when
compared to non-obese patients from the same time frame. This could be potentially concerning
given the most common indication for heparin was VTE. This dosing strategy in obese patients
may have led to underdosing, which could have resulted in a delay in therapeutic anticoagulation
or even an increased risk of thrombosis. This result was a surprising finding; therefore the
clinical implication was not collected in our study. However, an increased risk of thrombosis is
unlikely given the fact that there is no difference in the second aPTT values below the
therapeutic range or the time to achieve the first therapeutic aPTT between obese and non-obese
patients. In addition, the mean infusion rate required to achieve the first therapeutic aPTT was
closer to the initial infusion rate in obese patients than non-obese patients.
Although the time to first therapeutic aPTT was not different between the obese and nonobese cohorts, obese patients achieved therapeutic anticoagulation more rapidly when AdjBW
instead of ABW was used for dose calculation. This improvement was also reflected in the
higher percentage of obese patients who achieved therapeutic aPTT within 24 hours after
protocol modification. Since achieving therapeutic anticoagulation within 24 hours of starting
intravenous heparin for VTE was associated with decreased occurrence of recurrent
thromboembolism2,26, this improvement observed in our study is clinically relevant.
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Several studies have been conducted to address heparin dosing in obese patients. Barletta
et al. evaluated 101 patients who received the same high-intensity heparin protocol used in our
study, dosed based on ABW without maximum dose limits.8 The authors found that aPTT
values at 6 and 12 hours were significantly higher and significantly more aPTT values at 12
hours were supratherapeutic in patients with BMI > 40 kg/m2 compared to those with BMI < 40
kg/m2. Despite the supratherapeutic aPTT values, no difference in bleeding was seen. The
authors suggested a maximum dose limitation but did not recommend any specific dosing. A
large prospective study by Riney et al. evaluated the mean infusion rate required to achieve
therapeutic aPTT in 273 patients who received 3 different heparin protocols based on ABW.10
The authors found that morbidly obese patients (BMI ≥ 40 kg/m2) requires significantly lower
infusion rate than overweight patients (BMI 25-39.9 kg/m2) and normal/underweight patients
(BMI < 25 kg/m2). They also found that supratherapeutic aPTT occurred more frequently in
morbidly obese patients. More clinical bleeding episodes were observed in the morbid obesity
group, although the difference was not statistically significant. No difference was seen in time to
therapeutic aPTT. The findings from both of these studies were consistent with our data before
the heparin protocol modification, although we did not find a significant difference in aPTT
values but found higher risk of bleeding when ABW was used for dosing in obese patients.
Spruill et al. evaluated a modified high-intensity heparin protocol (70 units/kg bolus
followed by 15 units/kg/hour dosed based on ABW) and found no difference in time to first
therapeutic aPTT or infusion rate required to achieve the therapeutic aPTT between obese and
non-obese patients.14 Although the definition of obesity in this study was the same as our study,
it is difficult to extrapolate their results as the study used a lower dose, only had 20 patients in
each group, and their obese patients weighed less (mean weight 95 kg). No information on
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thrombosis or bleeding were collected. Bauer et al. evaluated 1054 patients who received a
heparin protocol of 60 units/kg bolus followed by 12 units/kg/hour dosed based on ABW and
found no difference in percentage of patients with a therapeutic initial aPTT or bleeding among
four body mass index (BMI) quartiles.9 They did find that patients in the highest BMI quartile
(> 34.3 kg/m2) are more likely to have an APPT > 110 seconds. Majority of the patients in this
study received heparin for cardiac conditions, such as acute coronary syndrome, which makes it
difficult to extrapolate their results as the guidelines recommend maximum dose limits in these
patients.27,28 A small retrospective study by Dee and Thomas evaluated another modified highintensity heparin protocol, in which 10 obese patients (weighing more than 50% above IBW)
received an initial infusion rate at 15 units/kg/hour and 45 non-obese patients received 18
units/kg/hour (all had a maximum initial infusion of 2100 units/hour); all patients received a
bolus dose of 80 units/kg (maximum of 10,000 units).18 The authors found no difference in
percentage of patients achieving a therapeutic aPTT anytime during heparin treatment, time to
therapeutic aPTT or bleeding. It is difficult to interpret data from this study given its small
sample size and unusual definition of obesity. Gerlach et al. evaluated 62 critically ill patients
who received heparin infusions without a bolus at 12 units/kg/hour if obese (BMI 30-39.9 kg/m2)
or morbidly obese (BMI ≥ 40 kg/m2) and 16 units/kg/hour if BMI < 30 kg/m2. The authors
found 92% of all patients had at least one therapeutic aPTT, but only 55% reached steady state
which was defined as three consecutive aPTT within target range. No difference was seen in
time to first therapeutic aPTT, time to steady state or bleeding. Again the small sample size
makes it difficult to extrapolate the data from this study.
Although reducing the initial infusion rate is a strategy recommended by some, others
suggested using a modified dosing weight somewhere between the IBW and ABW. A
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retrospective study of 213 patients by Yee and Norton evaluated the same high-intensity heparin
protocol as our study and used a modified dosing weight (IBW + 0.3*[ABW-IBW]) in patients
who weighed more than 10 kg above IBW.17 The authors found that the mean first aPTT values
were significantly lower in obese patients when a modified dosing weight was used for heparin
dose calculation compared to non-obese patients in which ABW was used. This finding is
similar to our study, although the authors did not report whether lower numeric values resulted in
more subtherapeutic aPTT values. This study used 0.3 as the adjustment factor for a modified
dosing body weight and obesity was defined as more than 10 kg above IBW with only 12% of
the patients weighing more than 100 kg. The lower dosing weight and lower threshold for
obesity likely explain the lower aPTT values seen in this study. Schwiesow et al. reported that
using the average of IBW and ABW to dose heparin in a morbidly obese patient (BMI 75 kg/m2,
182 kg) achieved therapeutic aPTT within 10 hours and was maintained for 6 days.19 A case
series by Khan et al. evaluated the average infusion rate required to achieve therapeutic aPTT in
8 patients and concluded that the infusion rate is close to the dose calculated based on AdjBW
(same formula used in our study).20 Myzienski et al. reported a case of under-anticoagulation
when maximum initial bolus and infusion rate were used in a morbidly obese patient (BMI 134
kg/m2, 388 kg). The authors indicated that the final infusion rate required to achieve therapeutic
aPTT more closely resembled the dose calculated using AdjBW.21
The literature on heparin dosing in obesity patients is limited by small sample, mixed
heparin dose protocols for various indications, disparity in definition of obesity, or inconsistency
in the formula used to obtain a modified dosing body. Our study focused on only the highintensity heparin protocol without maximum dose limits, as recommended by the guidelines
based on a previous study by Raschke et al.2–5 We also excluded violation of the protocol,
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including those that transitioned from lower dose heparin protocol and those who received
customized doses or had dosing weight different from what the protocol specifies. In addition to
laboratory endpoints, we also evaluated clinically relevant endpoint such as time to therapeutic
aPTT and clinically significant bleeding. Lastly, the study design allowed us a before and after
look at the different dosing strategies to assess the impact of using AdjBW for dose calculation
in obese patients, while still allowing comparison between obese and non-obese patients.
Several limitations of this study, however, should be highlighted. Although sample size
was met in both the pre-implementation and post-implementation groups, it is possible that our
study still did not have enough power for the primary outcome since the sample size analysis was
done based on a previous small study. In addition, achieving one aPTT value in the therapeutic
range does not necessarily mean that the full anticoagulation effect or steady state of heparin has
been achieved, especially since a very low percentage of patients in our study had two
consecutive aPTT values in the therapeutic range. One also has to interpret the results of this
study with caution due to its retrospective nature. Two individuals collected data which may
have introduced selection bias into this study. Additional confounders, inaccuracy in
documentation, and other clinical variables may not have been evident during retrospective chart
reviews. Although we compared data between the pre-implementation and post-implement
periods, several factors other than the protocol modification could have contributed to the
differences we observed. These may include increased nursing experience with the heparin
protocol, improved monitoring and interventions from the pharmacy department, difference in
patient populations in the two time periods. Therefore, we refrained from comparing too many
endpoints between the two time periods and rather focused more on the comparison between
obese and non-obese cohorts within the same time period. Furthermore, given the large number
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of subtherapeutic aPTT values in the study, it would have been beneficial to collect data on
adverse events associated with subtherapeutic aPTTs. Finally, using aPTT, a surrogate marker,
as the primary outcome of our study may be a limitation in itself as some studies demonstrated
that aPTT measurement does not correlate well with anticoagulation effect of heparin, especially
in critically ill patients.3,29,30 In addition, the association between supratherapetuic aPTT values
and bleeding risk is unclear. Although our study did not show a significant difference in
supratherapeutic aPTT between obese and non-obese patients, we did observe an increased
incidence of clinically significant bleeding when ABW was used for dosing in obese patients.
Due to these limitations of aPTT as a reliable monitoring parameter, using antifactor Xa level for
heparin therapy may provide a better dose-response curve and require fewer blood samples and
dose adjustments.29
In our study, AdjBW was calculated using IBW + 0.4 * (ABW-IBW) to determine a
modified dosing weight for patients weighing 30% above their IBW. Other institutions have
utilized a variety of methods to account for lower dose requirement in obese patients, such as
using different formula to obtain a modified dosing weight, using ABW for dosing but reducing
the initial infusion rate, and setting a maximum dose for the bolus and/or initial infusion rate.
Future studies are needed to determine the appropriate weight for heparin dose calculation in the
obese population, as well as comparing the different strategies for dose modification in heparin
therapy. As more institutions transition from aPTT to antifactor Xa monitoring for heparin
therapy, studies of heparin dosing in obese population also need to be updated to evaluate how
the different dosing strategies affect antifactor Xa. Most importantly, larger studies need to be
conducted to assess the clinical consequence of over-anticoagulating or under-anticoagulating
obese patients, such as bleeding, recurrence of thrombosis, and length of hospital stay.
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CONCLUSION
Given the increasing prevalence of obesity and the elevated risk of thrombosis in this
population, it is important to determine an appropriate way to dose heparin in these patients to
achieve prompt therapeutic anticoagulation without increasing the risk of bleeding. Our study
demonstrated that using actual body weight in obese patients for heparin dosing resulted in
increased bleeding, while using a modified dosing body weight in these patients led to quicker
achievement of anticoagulation without increasing bleeding risk.
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Figure 1. Inclusion, Exclusion, and Group Assignments of Patients
aPTT = activated Partial Thromboplastin Time, IV = intravenous
Figure 2. Comparison of 1st Activated Partial Thromboplastin Time (aPTT) Values in
Obese Patients
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Table 1.
Baseline Characteristicsa
Pre-Implementation
Obese
Non-Obese
(n=76)
(n=92)
63.4 ± 15.6 64.0 ± 18.8
32 (42.1)
51 (55.4)
104.7 ± 11.5 71.9 ± 15.2
63.5 - 231
38.79 - 123
36.1 ± 8.1
24.1 ± 3.5
26.4 – 70.9
16.4 - 40
37.7 ± 17.2 34.7 ± 10.0

Post-Implementation
p Value Obese
Non-Obese
(n=77)
(n=148)
0.82
59.2 ± 11.7 67.3 ± 17.5
0.12
48 (62.3)
81 (54.7)
<0.001 138.7 ± 35.6 71.9 ± 14.9
90.3 – 263.1 38.6 – 106.6
<0.001 44.4 ± 10.4 24.4 ± 3.3
30.2 – 77.1
12.6 – 31.7
0.25
31.3 ± 4.3
33.0 ± 7.3

Characteristics
Age, yr, mean ± SD
Male, n (%)
ABW, kg, mean ± SD
ABW range, kg
BMI, kg/m2, mean ± SD
BMI range, kg/m2
Baseline aPTT, sec,
mean ± SD
Heparin Indication, n (%)
VTE
48 (63.1)
50 (54.3)
0.32
53 (68.8)
88 (59.5)
PE
30 (39.5)
21 (22.8)
27 (35.1)
37 (25.0)
DVT
17 (22.4)
25 (27.2)
18 (23.4)
35 (23.6)
PE with DVT
1 (1.3)
4 (4.3)
8 (10.4)
16 (10.8)
Atrial Fibrillation
13 (17.1)
12 (13.0)
0.60
14 (18.2)
27 (18.2)
Valve Replacement
9 (11.8)
5 (5.4)
0.22
4 (5.2)
14 (9.5)
Others
3 (3.9)
22 (24.0)
<0.001 5 (6.5)
13 (8.8)
≥ 2 indications
3 (3.9)
3 (3.3)
0.83
1 (1.3)
6 (4.1)
a
ABW = actual body weight, BMI = body mass index, aPTT = activated partial thromboplastin
time; VTE = venous thromboembolism, PE = pulmonary embolism, DVT = deep vein
thrombosis;

14.

p Value
<0.001
0.34
<0.001
<0.001
0.09

0.22

0.86
0.39
0.73
0.46
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Table 2.
Activated Partial Thromboplastin Time (aPTT) Measurements

Variable

Pre-Implementation
Obese
Non-Obese
(n=76)
(n=92)

Post-Implementation
p Value Obese
Non-Obese
(n=77)
(n=148)

First aPTT
Sec, Mean ± SD
119.3 ± 40.2 109.7 ± 38.7 0.12
94.0 ± 41.5 110.1 ± 40.6
Therapeutic, n (%)
8 (10.5)
14 (15.2)
0.50
13 (16.9)
31 (20.9)
Subtherapeutic, n (%)
14 (18.4)
20 (21.7)
0.73
30 (39.0)
29 (19.6)
Supratherapeutic, n (%)
54 (71.1)
58 (63.0)
0.35
34 (44.2)
88 (59.5)
a
Second aPTT
Sec, Mean ± SD
112.0 ± 37.9 96.2 ± 41.4
0.01
90.7 ± 35.5 97.3 ± 35.7
Therapeutic, n (%)
13 (17.8)
22 (25.6)
0.32
27 (37.5)
41 (31.1)
Subtherapeutic, n (%)
14 (19.2)
24 (27.9)
0.27
21 (29.2)
31 (23.5)
Supratherapeutic, n (%)
46 (63.0)
40 (46.5)
0.06
24 (33.3)
60 (45.5)
Patients with ≥ 1
59 (77.6)
70 (76.1)
0.96
59 (76.6)
109 (73.6)
therapeutic aPTT, n (%)
Time to first therapeutic
23.8
19.9
0.11
14.0
17.3
aPTT, hr, median
(14.1-36.7) (9.8-32.3)
(8.4-24.4) (7.4-28.7)
(interquartile range)
Time to first therapeutic
0.58
aPTT, hr, n (%)
< 24
31 (40.8)
43 (46.7)
44 (57.1)
76 (51.4)
24-48
20 (26.3)
20 (21.7)
13 (16.9)
27 (18.2)
> 48
8 (10.5)
7 (7.6)
2 (2.6)
6 (4.1)
a
2010: n=73 in obese vs. n=86 in non-obese; 2014: n=72 in obese vs. n=132 in non-obese

p Value

0.006
0.58
0.003
0.04
0.20
0.44
0.47
0.20
0.75
0.47

0.74
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Table 3.
Dosing Characteristics

Variable

Pre-Implementation
Obese
Non-Obese
(n=76)
(n=92)
42 (55.3%)
59 (64.1%)
76.5 ± 10
81.1 ± 14.5

Post-Implementation
p Value Obese
Non-Obese
(n=77)
(n=148)
0.31
54 (70.1%)
103 (69.6%)
a
0.08
79.3 ± 7.4
78.8 ± 6.5

Received bolus, n (%)
Bolus dose, units/kg,
mean ± SD
Absolute bolus dose,
8017 ± 2263 5834 ± 1335 <0.001 7848 ± 1382 5676 ± 1250
units, mean ± SD
Infusion rate at first
14.0 ± 4.0
15.8 ± 4.1
0.01
18.2 ± 3.9a
16.5 ± 4.0
therapeutic aPTT,
units/kg/hr, mean (SD)b
a
Calculated based on AdjBW
b
2010: n=59 in obese vs. n= 70 in non-obese; 2014: n=59 in obese vs. n=109 in non-obese

p Value
0.94
0.65
<0.001
0.008
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Table 4.
Bleeding Events

Variable

Pre-Implementation
Obese Non-Obese p Value
(n=76) (n=92)
8 (10.5) 1 (1.1)
0.01

Clinically Significant
Bleeding, n (%)
Major Bleeding, n (%)
6 (7.9)
Clinically Relevant
2 (2.6)
Nonmajor Bleeding, n (%)

1 (1.1)
0 (0)

0.047
0.20

Post-Implementation
Obese Non-Obese p Value
(n=77) (n=148)
7 (9.1) 18 (12.2)
0.66
4 (5.2)
3 (3.9)

10 (6.8)
8 (5.4)

0.78
0.75
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Table 5.
Time to First Therapeutic Activated Partial Thromboplastin Time (aPTT)
Variable
Time to first therapeutic aPTT,
hr, median (interquartile range)
Time to first therapeutic aPTT,
hr, n (%)
< 24
≥ 24

Pre-Implementation
Obese (n=76)
23.8
(14.1-36.7)

Post-Implementation
Obese (n=77)
14.0
(8.4-24.4)

p Value
0.002
0.02

31 (40.8)
28 (36.8)

44 (57.1)
15 (19.5)

